5 completed, 2 terminated, 2 unknown, 2 withdrawn. 12 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 12 | Completed 5, Terminated 2, Unknown 2, Withdrawn 2, Active not recruiting 1 |
Follow Bipolar Disorder: new trials by email Literature Review of Bipolar Disorder trials Research Report on Bipolar Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Potentiation Disruption Underlying Cognitive Impairment in ECT Electroconvulsive Therapy - Major Depressive Disorder, Bipolar Disorder II | Early Phase 1 | Withdrawn | University of New Mexico | 2025-01-21 | 2026-01-21 | |
| Psychoneuromentalism Disorder: A Medical Condition That Affects People With Psychological Impairments From Health Issues Decompartmentalization Framework, Liquid Herbal TInctures, Mental Imagery - Schizoaffective Disorder, Bipolar Type, Bipolar Disorder | Early Phase 1 | Unknown | The Essence of Integrative Health and Medicine Practice | 30 | 2024-10-10 | 2024-08-12 |
| Pulse Width 0.15ms vs 0.30ms in Electroconvulsive Therapy Electroconvulsive therapy - Major Depressive Disorder, Bipolar Depression | Early Phase 1 | Unknown | Charles University, Czech Republic | 40 | 2022-01-18 | 2022-07-20 |
| Effects of Cannabis on Cognition and Endocannabinoid Levels in Bipolar Disorder Patients and Healthy Volunteers Dronabinol, Epidiolex, Placebos - Bipolar Disorder | Early Phase 1 | Terminated | University of California, San Diego | 19 | 2021-09-01 | 2024-05-10 |
| Treatment of Bipolar Depression With Pentoxifylline Pentoxifylline 400 MG - Bipolar Depression | Early Phase 1 | Completed | University Health Network, Toronto | 6 | 2021-07-12 | 2022-04-15 |
| Candesartan as an Adjunctive Treatment for Bipolar Depression Candesartan, Placebo - Bipolar Disorder Depression | Early Phase 1 | Withdrawn | The University of Texas Health Science Center, Houston | 2020-10-01 | 2022-04-27 | |
| Xenon Inhalation Therapy for Major Depressive Disorder and Bipolar Disorder Xenon, Nitrogen gas - Major Depressive Disorder, Bipolar Depression | Early Phase 1 | Completed | Massachusetts General Hospital | 13 | 2019-12-05 | 2026-10-09 |
| Ketamine Associated ACC GABA and Glutamate Change and Depression Remission: Ketamine - Major Depressive Disorder, Treatment Resistant Depression | Early Phase 1 | Active not recruiting | Mayo Clinic | 18 | 2019-01-03 | 2026-07-02 |
| Brain Imaging to Understand the Role of Inflammation in N-Acetyl Cysteine (NAC) Treatment of Bipolar Depression N-acetyl cysteine (NAC) - Bipolar Disorder, Depression | Early Phase 1 | Completed | Martin Lan | 3 | 2018-11-01 | 2021-08-05 |
| Nitrous TRD Bipolar Depression Nitrous Oxide, Placebo - Treatment- Resistant Bipolar Disorder, Bipolar Disorder | Early Phase 1 | Terminated | Washington University School of Medicine | 1 | 2016-03-25 | 2019-07-05 |
| Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression. Ketamine, Midazolam, Treatment as usual (TAU) - Major Depressive Disorder, Bipolar I Disorder | Early Phase 1 | Completed | Sunnybrook Health Sciences Centre | 9 | 2016-01-01 | 2017-07-26 |
| Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine D-cycloserine, DCS or placebo - Schizophrenia, Bipolar Disorder | Early Phase 1 | Completed | Mclean Hospital | 2 | 2015-09-27 | 2017-09-19 |
Depressive Disorder, Major (5) · Depression (3) · Psychotic Disorders (2) · Anxiety Disorders (1) · Attention Deficit Disorder with Hyperactivity (1) · Cognitive Dysfunction (1) · Dementia (1) · Depressive Disorder, Treatment-Resistant (1) · Disease (1) · Dissociative Disorders (1) · Fatigue (1) · Fatigue Syndrome, Chronic (1) · Inflammation (1) · Psychological Well-Being (1)
Bipolar and Related Disorders (12) · Mental Disorders (12) · Mood Disorders (12) · Depressive Disorder (5) · Behavior (4) · Behavioral Symptoms (3) · Neurocognitive Disorders (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Schizophrenia Spectrum and Other Psychotic Disorders (2) · Attention Deficit and Disruptive Behavior Disorders (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Chronic Disease (1) · Cognition Disorders (1)
Ketamine (2) · Acetylcysteine (1) · Breathing Exercises (1) · Cannabidiol (1) · Cycloserine (1) · Dietary Supplements (1) · Dronabinol (1) · Electroconvulsive Therapy (1) · Meditation (1) · Midazolam (1) · Mindfulness (1) · Music Therapy (1) · Nitrogen (1) · Nitrous Oxide (1) · Pentoxifylline (1)
Charles University, Czech Republic (1) · Martin Lan (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · Mclean Hospital (1) · Sunnybrook Health Sciences Centre (1) · The Essence of Integrative Health and Medicine Practice (1) · The University of Texas Health Science Center, Houston (1) · University Health Network, Toronto (1) · University of California, San Diego (1) · University of New Mexico (1) · Washington University School of Medicine (1)
United States (7) · Canada (2) · Czechia (1)
Andrew Nierenberg, MD (1) · Balwinder Singh, MD, MS (1) · Ben Palanca, MD (1) · Deborah L. Levy, Ph.D. (1) · Faith A Richardson, BSW, MPA, PhD (1) · Joshua D Rosenblat, MD, MSc (1) · Marsal Sanches, MD PhD (1) · William Perry, PhD (1)
PMID 15474895, PMID 31279534, PMID 33933839, PMID 34973601, PMID 35738038
P20GM109089 (1), R01DA043535 (1)